This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • Amryt receives reimbursement approval from NICE fo...
News

Amryt receives reimbursement approval from NICE for Myalepta as an adjunct to diet as replacement therapy for the treatment of leptin deficiency.

Read time: 1 mins
Published:21st Jan 2021
Amryt is pleased to announce that the National Institute for Health and Care Excellence (“NICE”) has approved Myalepta (metreleptin) for reimbursement in England and Wales as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy (GL) in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above. Myalepta received marketing authorisation from the European Medicines Agency (“EMA”) in 2018.
Condition: Lipodystrophy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights